Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy

American Journal of Cardiology

Volumn 101, Issue 8 SUPPL. 1, 2008, Pages

  Polonsky, Tamar S ^a   Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; RISK FACTORS; RISK REDUCTION BEHAVIOR; TRIGLYCERIDES;

EID: 41149139268     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.051     Document Type: Article

References (45)

1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf Accessed December 28, 2007
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., Kastelein J.J., Bittner V., Fruchart J.C., and Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
4. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., Kastelein J.J., LaRosa J.C., Schachner H., Shepherd J., Waters D.D., and Treating to New Targets (TNT) Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
5. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J.P., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Eng J Med 352 (2005) 1425-1435
6. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
9. De Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A.A., White H.D., Rouleau J.-L., Pedersen T.R., Gardner L.H., Mukherjee R., Ramsey K.E., et al., A to Z Investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 292 (2004) 1307-1316
10. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R., and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
11. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
12. Pederson T.R., Faergeman O., Kastelein J.J.P., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., Tsai J., and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
13. Castelli W.P., Garrison R.J., Wilson P.W.F., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
14. Assmann G., and Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 suppl (2004) iii8-iii14
15. Gordon D.J., and Rifkind B.M. High-density lipoprotein: the clinical implication of recent studies. N Engl J Med 321 (1989) 1311-1316
16. Chapmann M.J., Assmann G., Fruchart J.C., Shepherd J., and Sirtori C. Raising high-density cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
17. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
18. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., Corti R., Ruschitzka F., Lüscher T.F., and Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
19. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., and Haskard D.O. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103 (2001) 108-112
20. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W., and STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 92 (2003) 152-160
21. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., Jou J.T., Langendörfer A., Beere P.A., Watson D.J., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
22. The Long-Term Intervention With Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
23. Blankenhorn D.H., Johnson R.L., Nessim S.A., Azen S.P., Sanmarco M.E., and Selzer R.H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 8 (1987) 356-387
24. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
25. Sacks F.M., Rouleau J.-L., Moye L.A., Pfeffer M.A., Warnica J.W., Arnold J.M.O., Nash D.T., Brown L.E., Sestier F., Rutherford J., et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 75 (1995) 621-623
26. LaRosa J.C., Grundy S.M., Kastelein J.J., Kostis J.B., Greten H., and Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol 100 (2007) 747-752
27. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 suppl (1998) 7B-12B
28. Assmann G., Schulte H., Funke H., and von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 suppl (1998) M8-M14
29. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., McKenney J.M., Fonarow G.C., Maron D.J., Ansell B.J., Clark L.T., and Ballantyne C.M. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey: implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
30. Jacobson T.A., Miller M., and Schaefer E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29 (2007) 763-777
31. McKenney J.M., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
32. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation 107 (2003) 391-397
33. Gardner C.D., Fortmann S.P., and Krause R. Association of small LDL particles with incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
34. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
35. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
36. Kinlay S., Schwartz G.G., Anders G.O., Rifai N., Leslie S.J., Sasiela W.J., Szarek M., Libby P., Ganz P., and Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 (2003) 1560-1566
37. Chan A.W., Bhatt D.L., Chew D.P., Reginelli J., Schneider J.P., Topol E.J., and Ellis S.G. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107 (2003) 1750-1756
38. Nissen S.E., Tuzcu E.M., and Schoenhagen P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
39. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
40. Shepherd J., Blauw G.J., Murphy M.B., Bollen E., Buckley M.G., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al., PROSPER [Prospective Study of Pravastatin in the Elderly at Risk] Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360 (2002) 1623-1630
41. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 361 (2003) 1149-1158
42. Tonelli M., Isles C., Craven T., Tonkin A., Pfeffer M.A., Shepherd J., Sacks F.M., Furberg C., Cobbe S.M., Simes J., et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112 (2005) 171-178
43. Nissen S.E. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) trial. Am J Med 118 suppl (2005) 22-27
44. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double blind placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
45. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E., and PROVE IT-TIMI 22 [Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22] Investigators. Impact of triglyceride levels beyond low-density lipoprotein after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008) 724-730